Orders Over $30 Unlock Free Shipping
Orders Over $25 Unlock Free Shipping

Your cart

Your cart is empty

Check out these collections.

EcoBalance Cleansers
Dry Wipes

Bibliography for Aging Women 3-Part Series

  1. Bodner-Adler B, Alarab M, Ruiz-Zapata AM, Latthe P. Effectiveness of hormones in postmenopausal pelvic floor dysfunction-International Urogynecological Association research and development-committee opinion. Int Urogynecol J. 2019.
  2. Cagnacci A, Xholli A, Sclauzero M, Venier M, Palma F, Gambacciani M. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019;22(1):85-89.
  3. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. J Sex Med. 2017;14(3):413-424.
  4. Hoffmann JN, You HM, Hedberg EC, Jordan JA, McClintock MK. Prevalence of bacterial vaginosis and Candida among postmenopausal women in the United States. J Gerontol B Psychol Sci Soc Sci. 2014;69 Suppl 2:S205-214.
  5. Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321-1330.
  6. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497-515.
  7. Gliniewicz K, Schneider GM, Ridenhour BJ, et al. Comparison of the Vaginal Microbiomes of Premenopausal and Postmenopausal Women. Front Microbiol. 2019;10:193.
  8. Nienhouse V, Gao X, Dong Q, et al. Interplay between bladder microbiota and urinary antimicrobial peptides: mechanisms for human urinary tract infection risk and symptom severity. PLoS One. 2014;9(12):e114185.
  9. Erekson EA, Li FY, Martin DK, Fried TR. Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders. Menopause. 2016;23(4):368-375.
  10. Vongsa R, Hoffman D, Shepard K, Koenig D. Comparative study of vulva and abdominal skin microbiota of healthy females with high and average BMI. BMC microbiology. 2019;19(1):16.
  11. Thomas-White K, Forster SC, Kumar N, et al. Culturing of female bladder bacteria reveals an interconnected urogenital microbiota. Nat Commun. 2018;9(1):1557.
  12. Govender Y, Gabriel I, Minassian V, Fichorova R. The Current Evidence on the Association Between the Urinary Microbiome and Urinary Incontinence in Women. Front Cell Infect Microbiol. 2019;9:133.
  13. Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167-173.
  14. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. Jama. 2008;300(11):1311-1316.
  15. Alperin M, Burnett L, Lukacz E, Brubaker L. The mysteries of menopause and urogynecologic health: clinical and scientific gaps. Menopause. 2019;26(1):103-111.
  16. Sochocka M, Donskow-Lysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer's Disease-a Critical Review. Mol Neurobiol. 2019;56(3):1841-1851.
  17. Ticinesi A, Tana C, Nouvenne A. The intestinal microbiome and its relevance for functionality in older persons. Curr Opin Clin Nutr Metab Care. 2019;22(1):4-12.
  18. Zhuang ZQ, Shen LL, Li WW, et al. Gut Microbiota is Altered in Patients with Alzheimer's Disease. J Alzheimers Dis. 2018;63(4):1337-1346.
  19. Orr ME, Reveles KR, Yeh CK, Young EH, Han X. Can Oral Health and Oral-derived Biospecimens Predict Progression of Dementia? Oral Dis. 2019.
  20. Kunkle CM, Abernethy MG, Van Tongeren LR, Fashokun TB, Wright EJ, Chen CCG. Prevalence of cognitive impairment in older women with pelvic floor disorders. Int Urogynecol J. 2017;28(11):1645-1650.
  21. Nappi RE, Seracchioli R, Salvatore S, Cagnacci A, Di Paolantonio T, Busacca M. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. 2019;35(5):453-459.
  22. Ratner ES, Erekson EA, Minkin MJ, Foran-Tuller KA. Sexual satisfaction in the elderly female population: A special focus on women with gynecologic pathology. Maturitas. 2011;70(3):210-215.
  23. Woods NF, Rillamas-Sun E, Cochrane BB, et al. Aging Well: Observations From the Women's Health Initiative Study. J Gerontol A Biol Sci Med Sci. 2016;71 Suppl 1:S3-s12.
  24. Gopinath B, Kifley A, Flood VM, Mitchell P. Physical Activity as a Determinant of Successful Aging over Ten Years. Sci Rep. 2018;8(1):10522.
  25. Erekson EA, Fried TR, Martin DK, Rutherford TJ, Strohbehn K, Bynum JP. Frailty, cognitive impairment, and functional disability in older women with female pelvic floor dysfunction. Int Urogynecol J. 2015;26(6):823-830.
  26. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-1799.
  27. Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. J Sex Med. 2017;14(3):425-433.
  28. Binder RL, Freedman MA, Sharma KB, et al. Histological and Gene Expression Analysis of the Effects of Menopause Status and Hormone Therapy on the Vaginal Introitus and Labia Majora. J Clin Med Res. 2019;11(11):745-759.
  29. Fujimura T, Sato N, Ophaswongse S, et al. Characterization of vulvar skin of healthy Thai women: influence of sites, age and menopause. Acta Derm Venereol. 2013;93(2):242-245.
  30. Chen Y, Bruning E, Rubino J, Eder SE. Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage. Womens Health (Lond). 2017;13(3):58-67.
  31. Khadzhieva MB, Kolobkov DS, Kamoeva SV, Salnikova LE. Expression changes in pelvic organ prolapse: a systematic review and in silico study. Sci Rep. 2017;7(1):7668.
  32. Shynlova O, Bortolini MA, Alarab M. Genes responsible for vaginal extracellular matrix metabolism are modulated by women's reproductive cycle and menopause. Int Braz J Urol. 2013;39(2):257-267.
  33. Watson LJ, James KE, Hatoum Moeller IJ, Mitchell CM. Vulvovaginal Discomfort Is Common in Both Premenopausal and Postmenopausal Women. J Low Genit Tract Dis. 2019;23(2):164-169.
  34. Thomason A, Capps N, Lefler L, Richard-Davis G. Factors Affecting Gynecologic and Sexual Assessment in Older Women: A Lesson for Primary Care Providers. Healthcare (Basel). 2015;3(3):683-694.
  35. van der Veer C, Hertzberger RY, Bruisten SM, et al. Comparative genomics of human Lactobacillus crispatus isolates reveals genes for glycosylation and glycogen degradation: implications for in vivo dominance of the vaginal microbiota. Microbiome. 2019;7(1):49.
  36. de Castro-Sobrinho JM, Rabelo-Santos SH, Fugueiredo-Alves RR, et al. Bacterial vaginosis and inflammatory response showed association with severity of cervical neoplasia in HPV-positive women. Diagn Cytopathol. 2016;44(2):80-86.
  37. Kero K, Rautava J, Syrjanen K, Grenman S, Syrjanen S. Association of asymptomatic bacterial vaginosis with persistence of female genital human papillomavirus infection. Eur J Clin Microbiol Infect Dis. 2017;36(11):2215-2219.
  38. Hermansson RS, Olovsson M, Hoxell E, Lindstrom AK. HPV prevalence and HPV-related dysplasia in elderly women. PLoS One. 2018;13(1):e0189300.
  39. Ernstson A, Asciutto KC, Sturesson J, Noren J, Forslund O, Borgfeldt C. Detection of HPV mRNA in Self-collected Vaginal Samples Among Women at 69-70 Years of Age. Anticancer Res. 2019;39(1):381-386.
  40. Sodhani P, Gupta S, Gupta R, Mehrotra R. Bacterial Vaginosis and Cervical Intraepithelial Neoplasia: Is there an Association or is Co-Existence Incidental? Asian Pac J Cancer Prev. 2017;18(5):1289-1292.
  41. Gillet E, Meys JF, Verstraelen H, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One. 2012;7(10):e45201.
  42. Delwel S, Binnekade TT, Perez R, Hertogh C, Scherder EJA, Lobbezoo F. Oral hygiene and oral health in older people with dementia: a comprehensive review with focus on oral soft tissues. Clin Oral Investig. 2018;22(1):93-108.
  43. Fox M, Knorr DA, Haptonstall KM. Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective. Ann N Y Acad Sci. 2019;1449(1):3-24.
  44. Hill JM, Zhao Y, Clement C, Neumann DM, Lukiw WJ. HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling. Neuroreport. 2009;20(16):1500-1505.
  45. Sung CE, Huang RY, Cheng WC, Kao TW, Chen WL. Association between periodontitis and cognitive impairment: Analysis of national health and nutrition examination survey (NHANES) III. J Clin Periodontol. 2019;46(8):790-798.
  46. Olsson J, Lovheim H, Honkala E, Karhunen PJ, Elgh F, Kok EH. HSV presence in brains of individuals without dementia: the TASTY brain series. Dis Model Mech. 2016;9(11):1349-1355.
  47. Force UPST. Screening for Gynecologic Conditions With Pelvic Examination: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(9):947-953.
  48. Mitchell CM, Reed SD, Diem S, et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(5):681-690.
  49. Crann SE, Cunningham S, Albert A, Money DM, O'Doherty KC. Vaginal health and hygiene practices and product use in Canada: a national cross-sectional survey. BMC Womens Health. 2018;18(1):52.
  50. Gonzalez NL, O'Brien KM, D'Aloisio AA, Sandler DP, Weinberg CR. Douching, Talc Use, and Risk of Ovarian Cancer. Epidemiology. 2016;27(6):797-802.
  51. Bruning E, Chen Y, McCue KA, Rubino JR, Wilkinson JE, Brown ADG. A 28 Day Clinical Assessment of a Lactic Acid-containing Antimicrobial Intimate Gel Wash Formulation on Skin Tolerance and Impact on the Vulvar Microbiome. Antibiotics (Basel). 2020;9(2).
  52. Okamoto N, Umehara K, Sonoda J, et al. Efficacy of the combined use of a mild foaming cleanser and moisturizer for the care of infant skin. Clin Cosmet Investig Dermatol. 2017;10:393-401.
  53. Dezzutti CS, Brown ER, Moncla B, et al. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One. 2012;7(11):e48328.
  54. Gali Y, Delezay O, Brouwers J, et al. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother. 2010;54(12):5105-5114.
  55. Adriaens E, Remon JP. Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis. 2008;35(5):512-516.
  56. Cunha AR, Machado RM, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, das Neves J, Palmeira-de-Oliveira R. Characterization of commercially available vaginal lubricants: a safety perspective. Pharmaceutics. 2014;6(3):530-542.
  57. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151-161.
  58. Fashemi B, Delaney ML, Onderdonk AB, Fichorova RN. Effects of feminine hygiene products on the vaginal mucosal biome. Microb Ecol Health Dis. 2013;24.
  59. Desmedt B, Vanhamme M, Vanhee C, Rogiers V, Deconinck E. Consumer protection provided by the European medical device and cosmetic legislation for condoms and lubricants. Regul Toxicol Pharmacol. 2019;103:106-112.
  60. Hu M, Zhou T, Dezzutti CS, Rohan LC. The Effect of Commonly Used Excipients on the Epithelial Integrity of Human Cervicovaginal Tissue. AIDS research and human retroviruses. 2016;32(10-11):992-1004.
  61. Moench TR, Mumper RJ, Hoen TE, Sun M, Cone RA. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis. 2010;10:331.
  62. Raffai T, Burian K, Janovak L, et al. Vaginal Gel Component Hydroxyethyl Cellulose Significantly Enhances the Infectivity of Chlamydia trachomatis Serovars D and E. Antimicrob Agents Chemother. 2019;63(1).
  63. WHO/UNFPA/FHI. Use and procurement of additional lubricants for male and female condoms: . Geneva, Switzerland 2012.
  64. Brown JM, Poirot E, Hess KL, Brown S, Vertucci M, Hezareh M. Motivations for Intravaginal Product Use among a Cohort of Women in Los Angeles. PLoS One. 2016;11(3):e0151378.
  65. Fregosi NJ, Hobson DTG, Kinman CL, Gaskins JT, Stewart JR, Meriwether KV. Changes in the Vaginal Microenvironment as Related to Frequency of Pessary Removal. Female Pelvic Med Reconstr Surg. 2018;24(2):166-171.
  66. Tolppanen AM, Taipale H, Purmonen T, Koponen M, Soininen H, Hartikainen S. Hospital admissions, outpatient visits and healthcare costs of community-dwellers with Alzheimer's disease. Alzheimers Dement. 2015;11(8):955-963.
  67. Gupta A, Cox C, Dunivan GC, et al. Desire for Continued Pessary Use Among Women of Hispanic and Non-Hispanic Ethnic Backgrounds for Pelvic Floor Disorders. Female Pelvic Med Reconstr Surg. 2019;25(2):172-177.
  68. de Albuquerque Coelho SC, de Castro EB, Juliato CR. Female pelvic organ prolapse using pessaries: systematic review. Int Urogynecol J. 2016;27(12):1797-1803.
  69. Coelho SCA, Giraldo PC, Florentino JO, Castro EB, Brito LGO, Juliato CRT. Can the Pessary Use Modify the Vaginal Microbiological Flora? A Cross-sectional Study. Rev Bras Ginecol Obstet. 2017;39(4):169-174.
  70. Ramsay S, Tu le M, Tannenbaum C. Natural history of pessary use in women aged 65 - 74 versus 75 years and older with pelvic organ prolapse: a 12-year study. Int Urogynecol J. 2016;27(8):1201-1207.
  71. Collins S, Beigi R, Mellen C, O'Sullivan D, Tulikangas P. The effect of pessaries on the vaginal microenvironment. Am J Obstet Gynecol. 2015;212(1):60.e61-66.
  72. United States Food and Drug Administration. 510(k) Premarket Notification: K072741, Pre-Va Vaginal Lubricant. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K072741. Updated September 18, 2017. Accessed December 23, 2019.
  73. United States Food and Drug Administration. 510(k) Premarket Notification: K162319, BabyDance Fertility Lubricant. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K162319. Updated September 18, 2017. Accessed December 28, 2019.
  74. Ivarsson D, Wahlgren M. Comparison of in vitro methods of measuring mucoadhesion: ellipsometry, tensile strength and rheological measurements. Colloids and surfaces B, Biointerfaces. 2012;92:353-359.
  75. Mahan ED, Morrow KM, Hayes JE. Quantitative perceptual differences among over-the-counter vaginal products using a standardized methodology: implications for microbicide development. Contraception. 2011;84(2):184-193.
  76. Aslan E, Bechelaghem N. To 'douche' or not to 'douche': hygiene habits may have detrimental effects on vaginal microbiota. J Obstet Gynaecol. 2018;38(5):678-681.
  77. van de Wijgert J, Verwijs MC. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. Bjog. 2020;127(2):287-299.
  78. Nick G. 51+ Jaw Dropping App Usage Statistics In 2020. techjury. https://techjury.net/stats-about/app-usage/. Published 2019. Updated March 15, 2019. Accessed March 8, 2020.
  79. App Annie. The State of Mobile 2020. App Annie. https://www.appannie.com/en/go/state-of-mobile-2020/. Published 2020. Accessed March 8, 2020.
  80. Clarke MA, Rodriguez AC, Gage JC, et al. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis. 2012;12:33.
  81. Tucker KM, Godha K, Mirkin S, Archer DF. Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. Menopause. 2018;25(7):762-766.
  82. Gou P, Kraut ND, Feigel IM, et al. Carbon nanotube chemiresistor for wireless pH sensing. Sci Rep. 2014;4:4468.
  83. Liang Y, Chen M, Qin L, Wan B, Wang H. A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia. Infect Agent Cancer. 2019;14:29.
  84. Lewis FM, Bernstein KT, Aral SO. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. Obstet Gynecol. 2017;129(4):643-654.
  85. Graver MA, Wade JJ. Growth and Acidification by Vaginal Lactobacilli in Anaerobic Liquid Medium Over the pH Range 5.5 – 8.0. J Bacteriol Parasitol 2010;1(1):1-3.
  86. Zhou Y, Wang L, Pei F, et al. Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls. Front Cell Infect Microbiol. 2019;9:294.
  87. Anton L, Sierra LJ, DeVine A, et al. Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol. 2018;9:2181.
  88. Kleine-Lowinski K, Rheinwald JG, Fichorova RN, et al. Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer. 2003;107(3):407-415.
  89. Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub AY. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gynecol. 2019;220(4):324-335.
  90. Trifonova RT, Pasicznyk JM, Fichorova RN. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob Agents Chemother. 2006;50(12):4005-4010.
  91. Ayehunie S, Cannon C, Lamore S, et al. Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products. Toxicology in vitro : an international journal published in association with BIBRA. 2006;20(5):689-698.
  92. Klausner M, Ayehunie S, Breyfogle BA, Wertz PW, Bacca L, Kubilus J. Organotypic human oral tissue models for toxicological studies. Toxicology in vitro : an international journal published in association with BIBRA. 2007;21(5):938-949.
  93. Canny GO, Trifonova RT, Kindelberger DW, Colgan SP, Fichorova RN. Expression and function of bactericidal/permeability-increasing protein in human genital tract epithelial cells. J Infect Dis. 2006;194(4):498-502.
  94. Fichorova RN, Yamamoto HS, Delaney ML, Onderdonk AB, Doncel GF. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. mBio. 2011;2:6. e00168-00111.
  95. Meriwether KV, Rogers RG, Craig E, Peterson SD, Gutman RE, Iglesia CB. The effect of hydroxyquinoline-based gel on pessary-associated bacterial vaginosis: a multicenter randomized controlled trial. Am J Obstet Gynecol. 2015;213(5):729.e721-729.
  96. U.S. National Library of Medicine. Clinical Trials.gov: Postmenopausal Pessary Users: Estrogen Versus Trimosan. https://clinicaltrials.gov/ct2/show/NCT03943823?term=trimo-san&draw=2&rank=2. Published 2019. Updated May 9, 2019. Accessed December 28, 2019.
  97. Glyciome In-house data. In:2019.
  98. Paternoster DM, Tudor L, Milani M, Maggino T, Ambrosini A. Efficacy of an acidic vaginal gel on vaginal pH and interleukin-6 levels in low-risk pregnant women: a double-blind, randomized placebo-controlled trial. J Matern Fetal Neonatal Med. 2004;15(3):198-201.
  99. Fiorilli A, Molteni B, Milani M. Successful treatment of bacterial vaginosis with a policarbophil-carbopol acidic vaginal gel: results from a randomised double-blind, placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol. 2005;120(2):202-205.
  100. Malani M, Molteni B, Silvani I. Effect on Vaginal pH of a Polycarbophil Vaginal Gel Compared with an Acidic Douche in Women with Suspected Bacterial Vaginosis: A Randomized, Controlled Study. Curr Ther Research. 2000;61:781-788.
  101. Yamamoto HS, Xu Q, Fichorova RN. Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. BMC microbiology. 2013;13(1):4.
  102. Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod. 2004;71(3):761-769.
  103. Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr. 2004;37 Suppl 3:S184-193.
  104. Mauck CK, Ballagh SA, Creinin MD, et al. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr. 2008;49(3):243-250.
  105. Mauck CK, Lai JJ, Weiner DH, et al. Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure. AIDS Res Hum Retroviruses. 2013;29(11):1475-1486.
  106. Morrison C, Fichorova RN, Mauck C, et al. Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr. 2014;66(2):109-117.
  107. Fichorova RN, Chen PL, Morrison CS, et al. The Contribution of Cervicovaginal Infections to the Immunomodulatory Effects of Hormonal Contraception. MBio. 2015;6(5):e00221-00215.
  108. Thurman AR, Kimble T, Herold B, et al. Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. AIDS Res Hum Retroviruses. 2015;31(11):1139-1152.
  109. Mauck C, Chen PL, Morrison CS, et al. Biomarkers of Cervical Inflammation and Immunity Associated with Cervical Shedding of HIV-1. AIDS Res Hum Retroviruses. 2016;32(5):443-451.
  110. Thurman AR, Schwartz JL, Brache V, et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One. 2018;13(6):e0199778.
  111. Thurman A, Chandra N, Schwartz JL, et al. The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition. AIDS research and human retroviruses. 2019.
  112. Mahan ED, Zaveri T, Ziegler GR, Hayes JE. Relationships between perceptual attributes and rheology in over-the-counter vaginal products: a potential tool for microbicide development. PLoS One. 2014;9(9):e105614.
  113. Lim J. Hedonic scaling: A review of methods and theory. Food Quality and Preference. 2011;22:733-747.
  114. Scott D, Barnes A, Lister M, Arkell P. An evaluation of the user acceptability of chlorhexidine handwash formulations. J Hosp Infect. 1991;18 Suppl B:51-55.
  115. Knight A, Fouyaxis J, Jarrad G, Beski K, Cho G, Bidargadddi N. Systems to Harness Digital Footprint to Elucidate and Facilitate Ageing in Place. In: van den Berg MEL, Maeder AJ, eds. Telehealth for Our Ageing Society: Selected Papers from Global Telehealth 2017. Amsterdam: IOS Press BV; 2018:75-90.
  116. Bidargaddi N, Almirall D, Murphy S, et al. To Prompt or Not to Prompt? A Microrandomized Trial of Time-Varying Push Notifications to Increase Proximal Engagement With a Mobile Health App. JMIR Mhealth Uhealth. 2018;6(11):e10123.
  117. Bidargaddi N, Pituch T, Maaieh H, Short C, Strecher V. Predicting which type of push notification content motivates users to engage in a self-monitoring app. Prev Med Rep. 2018;11:267-273.
  118. Burchert S, Alkneme MS, Bird M, et al. User-Centered App Adaptation of a Low-Intensity E-Mental Health Intervention for Syrian Refugees. Front Psychiatry. 2018;9:663.
  119. Stoyanov SR, Hides L, Kavanagh DJ, Zelenko O, Tjondronegoro D, Mani M. Mobile app rating scale: a new tool for assessing the quality of health mobile apps. JMIR Mhealth Uhealth. 2015;3(1):e27.
  120. Akbar S, Coiera E, Magrabi F. Safety concerns with consumer-facing mobile health applications and their consequences: a scoping review. J Am Med Inform Assoc. 2019.
Back to References
Fast Shipping
Love it or It's Free Guarantee
Highly-Rated
Women-Owned Company
Sign Up for News
Giving Back